Integration of genome scale data for identifying new players in colorectal cancer

Viktorija Sokolova, Elisabetta Crippa, Manuela Gariboldi

Research output: Contribution to journalArticlepeer-review


Colorectal cancers (CRCs) display a wide variety of genomic aberrations that may be either causally linked to their development and progression, or might serve as biomarkers for their presence. Recent advances in rapid high-throughput genetic and genomic analysis have helped to identify a plethora of alterations that can potentially serve as new cancer biomarkers, and thus help to improve CRC diagnosis, prognosis, and treatment. Each distinct data type (copy number variations, gene and microRNAs expression, CpG island methylation) provides an investigator with a different, partially independent, and complementary view of the entire genome. However, elucidation of gene function will require more information than can be provided by analyzing a single type of data. The integration of knowledge obtained from different sources is becoming increasingly essential for obtaining an interdisciplinary view of large amounts of information, and also for cross-validating experimental results. The integration of numerous types of genetic and genomic data derived from public sources, and via the use of ad-hoc bioinformatics tools and statistical methods facilitates the discovery and validation of novel, informative biomarkers. This combinatory approach will also enable researchers to more accurately and comprehensively understand the associations between different biologic pathways, mechanisms, and phenomena, and gain new insights into the etiology of CRC.

Original languageEnglish
Pages (from-to)534-545
Number of pages12
JournalWorld Journal of Gastroenterology
Issue number2
Publication statusPublished - Jan 14 2016


  • Colorectal cancer
  • Copy number variations
  • Data integration
  • Gene expression
  • Methylome
  • MiRNA expression

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Integration of genome scale data for identifying new players in colorectal cancer'. Together they form a unique fingerprint.

Cite this